Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone Infusion Rate for Cancer Pain
NCT04296305Phase 4Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2020
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of hydromorphone in cancer pain, sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2020; status: active, not recruiting.
02
Drugs
hydromorphone
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT04296305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04296305.